GRAIL Stock Tumbles — National Health Service Galleri Trial To Blame

GRAIL Inc. (NASDAQ:GRAL) shares are down during Monday's premarket session following the release of results from the NHS-Galleri trial, which evaluated the effectiveness of the Galleri test in reducing late-stage cancer diagnoses.NHS-Galleri Trial ResultsThe NHS-Galleri trial results showed a favorable trend in reducing Stage IV cancer diagnoses, although the primary endpoint was not met. On Friday, GRAIL stock closed almost 51% lower.The trial evaluated annual multi-cancer screening with the Galleri test i ...